Henry Schein, Inc. HSIC
Healthcare · Medical Distribution · United States · S&P 500
Based on the available data, Henry Schein, Inc. gets an algorithmic score of 59/100. It trades at 84.97 $, with a bullish technical trend (RSI 41.3) and 25.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (5.4%).
- Low beta (0.56): defensive profile.
Weaknesses
- Thin net margin (3.0%): vulnerable to costs.
Fundamentals
| P/E | 25.06 |
| Forward P/E | 14.19 |
| PEG | 1.74 |
| P/B | 3.01 |
| EV/EBITDA | 13.60 |
| P/S | 0.71 |
| ROE % | 8.85 |
| ROA % | 4.39 |
| Gross margin % | 31.32 |
| Operating margin % | 5.76 |
| Net margin % | 2.96 |
| Revenue growth % (y/y) | 6.70 |
| Earnings growth % (y/y) | 17.10 |
| Revenue CAGR % | 1.40 |
| Earnings CAGR % | -9.56 |
| Debt/Equity % | 80.73 |
| Current ratio | 1.32 |
| FCF yield % | 5.38 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -5.1 % |
| 3 months | +1.7 % |
| 6 months | +16.9 % |
| YTD | +10.6 % |
| 1 year | +28.6 % |
| 3 years | +16.2 % |
| 5 years | +12.5 % |
Risk
| 1-year volatility | 25.5 % |
| Beta | 0.56 |
| 5-year max drawdown | -32.7 % |
| Sharpe 1A | 0.96 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.